Thrombospondin-1: a physiological regulator of nitric oxide signaling

被引:102
作者
Isenberg, J. S. [1 ]
Frazier, W. A. [2 ]
Roberts, D. D. [1 ]
机构
[1] NCI, Pathol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA
关键词
ischemic injury; tissue perfusion; angiogenesis; hemostasis; blood flow; nitric oxide; vascular smooth muscle; platelets;
D O I
10.1007/s00018-007-7488-x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Thrombospondin-1 is a secreted protein that modulates vascular cell behavior via several cell surface receptors. In vitro, nanomolar concentrations of thrombospondin-1 are required to alter endothelial and vascular smooth muscle cell adhesion, proliferation, motility, and survival. Yet, much lower levels of thrombospondin-1 are clearly functional in vivo. This discrepancy was explained with the discovery that the potency of thrombospondin-1 increases more than 100-fold in the presence of physiological levels of nitric oxide (NO). Thrombospondin-1 binding to CD47 inhibits NO signaling by preventing cGMP synthesis and activation of its target cGMP-dependent protein kinase. This potent antagonism of NO signaling allows thrombospondin-1 to acutely constrict blood vessels, accelerate platelet aggregation, and if sustained, inhibit angiogenic responses. Acute antagonism of NO signaling by thrombospondin-1 is important for hemostasis but becomes detrimental for tissue survival of ischemic injuries. New therapeutic approaches targeting thrombospondin-1 or CD47 can improve recovery from ischemic injuries and overcome a deficit in NO-responsiveness in aging.
引用
收藏
页码:728 / 742
页数:15
相关论文
共 142 条
[11]   Recent advances in cutaneous angiogenesis [J].
Bhushan, M ;
Young, HS ;
Brenchley, PEC ;
Griffiths, CEM .
BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (03) :418-425
[12]   Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13 [J].
Bonnefoy, A ;
Daenens, K ;
Feys, HB ;
De Vos, R ;
Vandervoort, P ;
Vermylen, J ;
Lawler, J ;
Hoylaerts, MF .
BLOOD, 2006, 107 (03) :955-964
[13]   A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrinogen, and GPIIbIIIa receptor [J].
Bonnefoy, A ;
Hantgan, R ;
Legrand, C ;
Frojmovic, MM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (08) :5605-5612
[14]   Combined inhibition of nitric oxide and prostaglandins reduces human skeletal muscle blood flow during exercise [J].
Boushel, R ;
Langberg, H ;
Gemmer, C ;
Olesen, J ;
Crameri, R ;
Scheede, C ;
Sander, M ;
Kjær, M .
JOURNAL OF PHYSIOLOGY-LONDON, 2002, 543 (02) :691-698
[15]   Integrin-associated protein (CD47) and its ligands [J].
Brown, EJ ;
Frazier, WA .
TRENDS IN CELL BIOLOGY, 2001, 11 (03) :130-135
[16]   Novel integrin antagonists derived from thrombospondins [J].
Calzada, MJ ;
Roberts, DD .
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (07) :849-866
[17]   Identification of novel β1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1 [J].
Calzada, MJ ;
Annis, DS ;
Zeng, BX ;
Marcinkiewicz, C ;
Banas, B ;
Lawler, J ;
Mosher, DF ;
Roberts, DD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (40) :41734-41743
[18]   α4β1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo [J].
Calzada, MJ ;
Zhou, L ;
Sipes, JM ;
Zhang, J ;
Krutzsch, HC ;
Iruela-Arispe, ML ;
Annis, DS ;
Mosher, DF ;
Roberts, DD .
CIRCULATION RESEARCH, 2004, 94 (04) :462-470
[19]   Recognition of the N-terminal modules of thrombospondin-1 and thrombospondin-2 by α6β1 integrin [J].
Calzada, MJ ;
Sipes, JM ;
Krutzsch, HC ;
Yurchenco, PD ;
Annis, DS ;
Mosher, DF ;
Roberts, DD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (42) :40679-40687
[20]   Cell contact-dependent activation of α3β1 integrin modulates endothelial cell responses to thrombospondin-1 [J].
Chandrasekaran, L ;
He, CZ ;
Al-Barazi, H ;
Krutzsch, HC ;
Iruela-Arispe, ML ;
Roberts, DD .
MOLECULAR BIOLOGY OF THE CELL, 2000, 11 (09) :2885-2900